Inactive disease
Original Article Clinically inactive disease status with tocilizumab every 4 weeks in refractory systemic-onset juvenile idiopathic arthritis
... We have shown that the dose of prednisone tapered when tocilizumab was given. However, we did not evaluate the reduction or discontinu- ation of DMARDs, which was another weakness of our study. The follow-up period was ...
9
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
... Figure 3 Switching of biological agents (BAs), and achievement of inactive disease and clinical remission (CR). ETA, etanercept; TCZ, tocilizumab. § The only patient on adalimumab (ADA) as first-line ...
9
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis
... the disease course in the individual patient and, hence, the treat- ment requirements at the onset of the disease [13, 21], a step-up approach is generally pursued of starting MTX and adding a biologic ...
8
Dynamics of vitamin D in patients with mild or inactive inflammatory bowel disease and their families
... Crohn’s disease (CD) or ulcerative colitis (UC) was based on accepted criteria from previous evaluations (history, physical examination, radiology and/or histology) ...Celiac disease, other malabsorptive ...
11
Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial
... Clinically inactive disease; DMARDs: Disease-modifying anti-rheumatic drugs; GH: General health perceptions; HrQoL: Health-related quality of life; JADAS: Juvenile arthritis disease activity ...
6
Chronic and recurrent non infectious paediatric onset uveitis: a French cohort
... with inactive disease for at least 6 months after discontinuation of all treatments for eye disease (including CS eye drops) were considered in ...for inactive uveitis (grade 0 cells applies ...
10
Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey
... achieving inactive disease did not significantly improve the overall flare ...with inactive disease > 12 months had significantly lower flare rates ...with disease activity, and that ...
7
Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
... [30]. Inactive disease (modified criteria) was defined as no active joints, a Physician’s Global Assessment (PGA) score of ≤10 mm, and a C-reactive protein (CRP) value of ...[14], inactive ...
11
Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease
... Behçet’s Disease cri- teria ...Behçet’s Disease Current Activity Form adapted for Portuguese by the Sociedade Brasileira de Reumatologia (sBR-BDCAF) ...autoimmune disease or ...Erythematosus ...
15
IL 37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity
... active disease showed higher IL-37 mRNAs and serum protein levels compared with those with inactive disease as well as healthy ...SLE disease activity, especially related with SLE renal ...
8
No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis
... at inactive disease, with three-monthly ...of inactive disease, treatment was ...Arthritis Disease Activity Score (JADAS)10-scores were available from all the patients ...ging ...
10
Impaired function of endothelial progenitor cells in children with primary systemic vasculitis
... of disease activity attending a single center (Great Ormond Street Hospital, London) between October 2008 and December ...with inactive disease, although non-significantly ...
10
Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis
... clinically inactive disease (Figure 4D and Supplemental Figure ...clinically inactive disease displayed an intermediate slope between treatment-naive patients and ...
14
The composition and functional protein subsystems of the human nasal microbiome in granulomatosis with polyangiitis: a pilot study
... S. aureus genomic analysis revealed that no clonal lineage dominated in GPA patients, and there was no evi- dence of transmission between patients, except in case of a single GPA patient and a HHC. This is similar to ...
17
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
... Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still ...
11
Frequency of Th9 Cells in Different Stages of Rheumatoid Arthritis
... the disease stages, the patients were divided into two subgroups: very early RA (VERA) and established ...RA. Disease duration in VERA patients was less than three months after the first signs of RA ...
7
The effect of interleukin-10 and of interleukin-12 on the anti-double-stranded DNA antibody production by the blood lymphocytes of patients with systemic lupus erythematosus
... chronic disease, the activity of which varies over time such that patients can sometimes be in full ...active disease and 0-5 relatively inactive ...
216
Comparing Levels of Depression in Healthy Active and Inactive Elders versus Those with Knee Osteoarthritis Disease
... osteoarthritis disease, (c) Over a year of their disease diagnosis, and the absence of any chronic disease like cancer, multiple sclerosis, asthma, renal failure, heart failure, diabetes, and ...
8
High-Mobility Group Box-1 Protein (HMGB1) Is Increased in Antineutrophilic Cytoplasmatic Antibody (ANCA)-Associated Vasculitis with Renal Manifestations
... ity, called grumbling disease (29). There is a need for improved biomarkers to predict drug responsiveness, relapse risk, as well as detection of subclinical disease activity. Recently, IL-18 was found to ...
7
"Inactive" Ingredients in Pharmaceutical Products
... Lackey SD Sr Hypersensitivity to tartrazine (FD&C Yellow No. 5) and other dyes and additives present in foods and pharmaceutical products. Michaelsson G, Juhlin L: Urticaria induced [r] ...
11